XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(Q2)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q2)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q2)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q4)Dec 31, 2021 | (Q2)Jun 30, 2021 | |
---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash cash equivalents and federal funds sold | -6.67%145.08K | -99.18%10.78K | -99.18%10.78K | -7.46%155.45K | -80.44%1.31M | -80.44%1.31M | -94.09%167.97K | 43.96%6.7M | 43.96%6.7M | -4.75%2.84M |
-Cash and cash equivalents | -6.67%145.08K | -99.18%10.78K | -99.18%10.78K | -7.46%155.45K | -80.44%1.31M | -80.44%1.31M | -94.09%167.97K | 43.96%6.7M | 43.96%6.7M | -4.75%2.84M |
Receivables | 170.84%3.45M | 5.99%2.34M | 5.99%2.34M | -66.81%1.27M | -5.53%2.21M | -5.53%2.21M | 114.87%3.84M | 41.63%2.34M | 41.63%2.34M | 105.50%1.79M |
-Available for sale securities | -81.86%509.92K | 142.80%3.34M | 142.80%3.34M | --2.81M | --1.38M | --1.38M | ---- | ---- | ---- | ---- |
Deferred costs | --205.64K | --179.79K | --179.79K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Total assets | 2.84%1.03B | 8.79%1.01B | 8.79%1.01B | 4.12%1B | -23.30%925.91M | -23.30%925.91M | -18.65%964.18M | 7.00%1.21B | 7.00%1.21B | 16.88%1.19B |
Liabilities | ||||||||||
Payables | 46.21%3.19M | 245.50%3.67M | 245.50%3.67M | -68.87%2.18M | -64.23%1.06M | -64.23%1.06M | 185.12%7.02M | 78.27%2.97M | 78.27%2.97M | 199.47%2.46M |
-Accounts payable | ---- | ---- | ---- | ---- | ---- | ---- | --6.2M | ---- | ---- | ---- |
-Other payable | 46.21%3.19M | 245.50%3.67M | 245.50%3.67M | 166.35%2.18M | -64.23%1.06M | -64.23%1.06M | -66.68%820.2K | 78.27%2.97M | 78.27%2.97M | 199.47%2.46M |
Derivative product liabilities | -30.88%8.66M | 107.44%11.27M | 107.44%11.27M | 108.09%12.52M | -62.77%5.43M | -62.77%5.43M | -57.92%6.02M | -21.22%14.59M | -21.22%14.59M | -28.22%14.3M |
Total liabilities | -20.33%12.11M | 120.69%15.34M | 120.69%15.34M | 14.44%15.2M | -61.10%6.95M | -61.10%6.95M | -22.29%13.28M | -13.49%17.87M | -13.49%17.87M | -18.75%17.09M |
Shareholders'equity | ||||||||||
Share capital | 0.00%1.1M | 0.00%1.1M | 0.00%1.1M | 0.13%1.1M | 0.68%1.1M | 0.68%1.1M | 1.76%1.09M | 1.28%1.09M | 1.28%1.09M | 0.07%1.08M |
-common stock | 0.00%1.1M | 0.00%1.1M | 0.00%1.1M | 0.13%1.1M | 0.68%1.1M | 0.68%1.1M | 1.76%1.09M | 1.28%1.09M | 1.28%1.09M | 0.07%1.08M |
Paid-in capital | -8.55%315.34M | -8.55%315.34M | -8.55%315.34M | -2.14%344.81M | -0.35%344.81M | -0.35%344.81M | 0.29%352.34M | -1.27%346.03M | -1.27%346.03M | -9.63%351.34M |
Retained earnings | 9.50%703.87M | 17.88%675.51M | 17.88%675.51M | 7.59%642.8M | -31.96%573.06M | -31.96%573.06M | -26.76%597.46M | 11.40%842.2M | 11.40%842.2M | 35.23%815.79M |
Total stockholders'equity | 3.20%1.02B | 7.94%991.94M | 7.94%991.94M | 3.98%988.7M | -22.73%918.96M | -22.73%918.96M | -18.60%950.9M | 7.38%1.19B | 7.38%1.19B | 17.63%1.17B |
Total equity | 3.20%1.02B | 7.94%991.94M | 7.94%991.94M | 3.98%988.7M | -22.73%918.96M | -22.73%918.96M | -18.60%950.9M | 7.38%1.19B | 7.38%1.19B | 17.63%1.17B |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Audit Opinions | -- | Unqualified Opinion | -- | -- | Unqualified Opinion | -- | -- | Unqualified Opinion | -- | -- |